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BIOLOGYAdoptive Immunotherapy Against Allogeneic Kidney
Grafts in Dogs with Stable Hematopoietic Trichimerism
Scott S. Graves,1,2 William J. Hogan,1 Christian Kuhr,1,2 Razvan Diaconescu,1
Michael Harkey,1 George E. Sale,1,2,3 Brad Stone,4 George E. Georges,1,2 Rainer Storb1,2
Dogs given nonmyeloablative conditioning and marrow grafts from 2 dog leukocyte antigen (DLA)-identical
littermate donors developed stable trichimerism and stably accepted a subsequent kidney graft from one of
the marrow donors without the need for immunosuppression. In this study, we used trichimeras to evaluate
strategies for adoptive immunotherapy to solid tumors, using the kidney as a tumor surrogate. Three DLA-
identical trichimeric recipients were established by simultaneously infusing marrow from 2 DLA-identical do-
nor dogs into a DLA-identical recipient conditioned with 2 Gy of total body irradiation (TBI) and given a short
course of postgraft immunosuppression. After stable hematopoietic engraftment was confirmed, a kidney was
transplanted from 1 of the 2 marrow donors into each respective trichimeric recipient. Peripheral blood lym-
phocytes from each kidney donor were then used to sensitize the alternate marrow donor. The trichimeric
recipients were given donor lymphocyte infusions (DLIs) from the sensitized dogs and monitored for chime-
rism, graft-versus-host disease (GVHD), and kidney rejection. After DLI, we observed both prompt rejection
of the transplanted marrow and donor kidney and disappearance of corresponding hematopoietic chimerism.
Presumably due to shared minor histocompatibility antigens, host chimerism also disappeared, and GVHD in
skin, gut, and liver developed. The native kidneys, although exhibiting lymphocytic infiltration, remained func-
tionally normal. This study demonstrates that under certain experimental conditions, the kidney—an organ
ordinarily not involved in graft-versus-host reactions—can be targeted by sensitized donor lymphocytes.
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Graft-versus-host diseaseINTRODUCTION
Graft-versus-tumor effects against hematologic
malignancies after major histocompatibility complex–
identical allogeneic hematopoietic cell transplantation
(HCT) are the result of donor lymphocyte activity
against minor histocompatibility (H) antigens ex-
pressed on hematopoietic cells [1,2]. Target minor H
antigens include both ubiquitously expressed antigens
and those specific for hematopoietic cells. Given these
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doi:10.1016/j.bbmt.2008.08.005observations with blood cancers, clinicians have been
quick to explore whether allogeneic graft-versus-tumor
effects might exist and might be therapeutically ex-
ploited in various metastatic solid tumors. Malignancies
evaluated include colon, breast, prostate, and renal can-
cers, among others [3-7]. Outcomes have been variable.
Convincing graft-versus-tumor effects have been re-
ported in a minority of patients with colon and renal
cell cancer and possibly breast cancer, whereas patients
with other types of malignancy have shown no response.
Previous work in our laboratory evaluated whether
graft-versus-host (GVH) reactions, typically directed
against hematopoietic cells, skin, gut, and liver, could
be diverted to reliably include metastatic solid malig-
nancies [8]. In these experiments, we used a canine
HCT model in which the kidney served as a surrogate
tumor target. The experiment was designed to deter-
mine whether adoptive immunotherapy could result
in rejection of a specific organ not ordinarily involved
in GVH reactions. Stable mixed chimerism in this
model was maintained by regulatory T cells [9,10]
and could not be dislodged by infusion of naı¨ve donor
lymphocytes [11]. To shift mixed chimerism to1201
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ease (GVHD), donor lymphocytes were sensitized to
host minor H antigens [8]. Accordingly, after mixed
chimerism was established in donor lymphocyte anti-
gen (DLA)-identical littermate recipients, the marrow
donors underwent transplantation of kidneys from
their respective mixed chimeric recipients, which
they rejected within 3 to 5 weeks. When marrow donor
lymphocytes harvested after kidney graft rejection
were injected into the recipients, the mixed hemato-
poietic chimerism converted to full donor chimerism.
But although 2 of 5 dogs developed GVHD, the resid-
ual native kidneys, which expressed the same minor an-
tigens used to sensitize the donor, were not targeted by
the adoptively transferred lymphocytes. Thus, al-
though marrow donors readily rejected their recipi-
ents’ kidneys and thereby became sensitized to the
mixed chimeras’ ubiquitously expressed minor H anti-
gens, as evidenced by elimination of host hematopoie-
sis and GVHD, the level of sensitization apparently
was insufficient to induce immunologic damage to
the recipients’ remaining kidneys.
To investigate this question further, we developed
a trichimeric model in which marrow from each of 2
DLA-identical littermate donors was transplanted si-
multaneously into a third littermate conditioned with
2 Gy of total body irradiation (TBI) and given a short
course of postgraft immunosuppression [12]. A kidney
heterotopically transplanted from 1 of the 2 marrow
donors into the groin of each trichimeric recipient
was stably accepted and then served as a solid organ
surrogate for graft-versus-‘‘tumor’’ reactions. Toward
this end, the other marrow donor was sensitized
against H antigens of the marrow/kidney donor, and
sensitized lymphocytes were subsequently infused
into the respective trichimeras. The heterotopic loca-
tion of the kidney grafts facilitated histological moni-
toring for lymphocyte infiltration and rejection. In
addition, we postulated that the kidney transplantation
would give rise to danger signals [13], thereby increas-
ing the likelihood of becoming targets for lymphocytes
sensitized to minor H antigens.
MATERIALS AND METHODS
Dogs
Litters of beagles and beagle/mini-mongrel mixes
were raised at the Fred Hutchinson Cancer Research
Center and assessed for disease. They received a pre-
ventive medicine program against worms, distemper,
parvovirus, adenovirus (type 2), parainfluenza virus,
corona virus, rabies, and canine papilloma virus. The
dogs were aged 7 to 9 months (median, 8 months)
and weighed 7.2 to 12.3 kg (median, 8.5 kg). The study
design was approved by the Institutional Animal Care
and Use Committee of the Fred Hutchinson CancerResearch Center (which is accredited by the Associa-
tion for Assessment and Accreditation of Laboratory
Animal Care International). Selection of donor/recip-
ient triplets included typing of litters and parents to
determine the identity of triplets for highly polymor-
phic microsatellite markers within DLA class I and
class II regions [14], which was confirmed by DLA-
DRB1 gene sequencing [15].
Marrow Grafts
On day 0, recipients were treated with 2 Gy of TBI
and subsequent i.v. infusion of marrow from donors 1
and 2, as described previously (Figure 1A) [12,16].
Bone marrow was aspirated from the humeri of anes-
thetized donors by vacuum pump aspiration. In brief,
the skin over the humeral heads was surgically pre-
pared. Using sterile technique, a long aspiration needle
was inserted into the marrow cavity of the shoulder
joint. The needle was connected by surgical tubing
to a vacuum flask containing heparin. Approximately
150 mL of a blood–marrow mixture was collected
per donor. The mixture was passed through 0.307-
and 0.201-mm diameter stainless steel mesh screens.
Nucleated marrow cell counts were corrected for
white blood cell content. Marrow from both donors
was infused into the recipients through the cephalic
vein, with an approximate 2-hour interval between in-
fusions. The marrow grafts from individual donors
Figure 1. A, Schema for generating trichimeric marrow recipients and
kidney transplant rejection. After 2 Gy TBI (1), marrow from 2DLA-iden-
tical donors was simultaneously injected into the recipient (2). Postgraft-
ing immunosuppression with CSP and MMF followed for 35 and 28 days,
respectively (3). B, After stable trichimerism was established, a kidney
was transplanted from donor 2 into the recipient (4). Once stable kidney
engraftment was verified, donor 1 was sensitized against minor H anti-
gens of donor 2 with 3 PBMC injections (5). After DLI from sensitized
donor 1 into the trichimeric recipient (6), the dogs were monitored
for a shift in donor chimerism, GVHD, and kidney graft rejection (7).
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(range, 3.6 to 6.1 108). The dogs received supportive
postgraft care. Immunosuppression consisted of oral
cyclosporine (CsA), 15 mg/kg orally twice daily on
days 21 to 35, and mycophenolate mofetil (MMF),
10 mg/kg s.c. twice daily on days 0 to 27 [17]. The
MMF dosage was adjusted according to clinical toxic-
ity, involving gastrointestinal distress.
Chimerism Analysis
Chimerism analyses were conducted on peripheral
blood mononuclear cells (PBMCs) and granulocytes
after separation of blood on Ficoll (density 5 1.074),
on marrow cells after buffered NH4Cl lysis of red cells
[12], and on sections of kidney allografts collected at
necropsy. For the latter, infiltrating lymphocytes
were collected from the minced sections of resected
kidneys after 16 hours of incubation (37C, 5% CO2)
through methods similar to those described previously
[18], but without the use of enzymatic digestion. After
the resected minced kidney tissue was incubated over-
night in RPMI medium (Gibco/Invitrogen, Carlsbad,
CA) plus 10% heat-inactivated dog serum, the cells
were layered over Ficoll (density 1.074) and centrifuged
at 1100  g for 40 minutes. Cells at the interface were
collected and washed in phosphate-buffered saline by
centrifugation. The contributions of recipient and do-
nor cells to peripheral blood and other hematopoietic
tissues and kidney were quantified by fluorescent vari-
able-number tandem repeat (VNTR) polymerase chain
reaction (PCR) analysis, as described previously [12].
Kidney Transplantation
Kidney allografting from 1 of the marrow donors
(donor 2) to the respective trichimeric marrow recipi-
ents was performed as described previously [19]. In brief,
donor 2 was anesthetized, a midline laparotomy was
performed, and the left kidney was exposed. The ureter,
renal vein, and renal artery were secured and transected.
The kidney was removed from the body cavity and per-
fused with 4C saline containing 10 U/mL of heparin.
The kidney was maintained in cold heparinized saline
while the recipient was prepared for surgery. The kidney
was subsequently transplanted into the trichimeric re-
cipient’s right anterior thigh; the renal artery and vein
were anastamosed to the femoral artery and vein, respec-
tively; and the ureter was implanted into the bladder [8].
The kidney graft recipients received no immunosup-
pressive therapy. The vascularity of the transplanted
kidney was confirmed by an ultrasonic Doppler flow
detector (Parks Medical Electronics, Aloha, OR). At
least 2 biopsies of transplanted kidneys were performed
before study completion. The tissue specimens were
fixed in 10% buffered formalin and stained using hema-
toxylin and eosin for evaluation by microscopy. Kidney
volume was calculated based on techniques for measur-ing xenograft tumor volume using the formula 0.1667
(LW2), where L (length) and W (width) are orthogo-
nal measurements of kidney diameter [20].
Donor Sensitization and Donor Lymphocyte
Infusion (DLI)
Marrow donor 1 was sensitized to H antigens from
donor 2 (marrow1 kidney donor) using a mean of 4.6
 107 PBMCs (range, 1.6 to 8.5  107) (Figure 1B).
Toward that end, 50 mL of blood was collected from
the kidney donor on each of 3 occasions, 10 days apart.
Half of the volume was injected intravenously, and the
other half was treated with ammonium chloride lysing
solution (155 mM ammonium chloride, 10 mM
sodium bicarbonate, 0.1 mM EDTA), washed, and
injected subcutaneously into the flank of the first
marrow donor. Ten days after the third injection, leu-
kopheresis was performed on donor 1 through a central
venous catheter in the external jugular vein using a
continuous-flow centrifuge (COBE 2997; Blood
Component Technology, Lakewood, CO) [21,22].
RESULTS
Three stable hematopoietic trichimeric dogs
received a kidney transplant from 1 of their marrow do-
nors 25 to 40 weeks after marrow grafting without post-
graft immunosuppression [12]. All of the dogs’
hematologic profiles and blood chemistries were within
normal ranges. Table 1 shows that host cell contribu-
tions at the time of kidney transplantation and DLI
ranged from 1% to 20% of peripheral blood granulo-
cytes and from 16% to 50% of lymphocytes. Hemato-
poietic chimerism contributions from marrow donor 1
ranged from 18% to 96.9% of granulocytes and from
5% to 53% of lymphocytes, whereas those from marrow
donor 2 (marrow1 kidney) were 0.1% to 68% and 19%
to 56% for the 2 respective populations. Two of the tri-
chimeric recipients (G362 and G643) did not receive
immunosuppressive therapy after day 35 after marrow
grafting. Dog G513 required 15 weeks of CsA (7.5
mg/kg with taper to 2.5 mg/kg) before successful resolu-
tion of GVHD; in this dog, an additional 14 weeks
elapsed between discontinuation of CsA and kidney
transplantation. The kidneys were negative for lympho-
cytic infiltration for 17 to 23 weeks before DLI, as as-
sessed by histological examination of needle biopsy
specimensandmeasurementofkidneyvolume(Figure2,
left column). Trichimerism remained stable and un-
changed between kidney transplantation and DLI.
Effect of DLI on Kidney Allografts and Native
Trichimeric Kidneys
In each of the 3 sets of littermates, marrow donor 1
was sensitized against marrow/kidney donor 2 with 3
injections of PBMCs administered 10 days apart.
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Percent Chimerism at Time of (Weeks after Transplantation)
Kidney Transplant DLI Euthanasia GVHD After
Trichimeric Recipient Granulocytes PBMCs Granulocytes PBMCs Granulocytes PBMCs Kidney Transplant DLI
G 362 (25)* (48) (56)
Donor 1 33 28 30 28 100 99
Donor 2† 66 43 68 56 0 1
Recipient 1 29 2 16 0 0 No S, G, L
G 513 (40) (56) (59.5)
Donor 1 96.9 53 87.4 39 91 86
Donor 2† 0.1 19 0.2 34 6 1
Recipient 3 28 12.4 27 3 13 No S, G, L
G 643 (26) (44) (49)
Donor 1 28 5 18 17 95 94
Donor 2† 55 45 62 49 4 5
Recipient 17 50 20 34 1 1 No S, G, L
*Weeks after HCT.
†Donor 2 donated 1 kidney to the trichimeric recipient. Donor 1 underwent apheresis after 3 injections of peripheral blood donated by donor 2. The
apheresis product was injected i.v. into the trichimeric recipient dog. Percent chimerism of each of the trichimeric dogs was determined before kidney
transplantation, DLI, and at the time of euthanasia. Blood for serum chemistry analysis was collected before and after kidney transplantation and within
1 week before euthanasia of the trichimeric kidney recipients. GVHD was diagnosed for skin (S), gut (G), and liver (L) at necropsy.Ten days after the final injection, a mean of 4.2 108
PBMCs (range, 2.5 to 5.1 108) was harvested from
sensitized donor 1 and injected into the respective tri-
chimeric recipient.
Within a mean of 7 days after DLI (range, 3 to 15
days), the transplanted kidney volumes began to in-
crease in the 3 trichimeric recipients; for example, kid-
ney volume in one of the dogs increased by 162% in 28
days (data not shown). The biopsies of transplanted
kidneys revealed lymphocytic infiltration at various
time points after DLI (data not shown). Samples ob-
tained at necropsy demonstrated extensive tubulitis
and interstitial lymphocytic infiltration of the trans-
planted kidneys, consistent with acute severe rejection
(Figure 2, middle column). Periglomerular lympho-
cytic infiltration was observed in the trichimeric recip-
ients’ native kidneys, although these infiltrations were
far less pronounced than those in the allogeneic kid-
neys (Figure 2, right column). In dog G643, 73% of
the cells obtained from cultured transplanted kidney
tissue were from donor 1 and 27% were from donor
2, possibly due to contaminating kidney cells (data
not shown). Serum chemistry analysis after DLI found
normal serum creatinine and blood urea nitrogen
levels, indicating normal function of the recipients’ na-
tive kidneys (data not shown).
Chimerism
Before DLI, all 3 dogs had trichimerism that had
been stable for more than 9 months (Table 1). After
DLI, a rapid shift from mixed to nearly 100% donor 1
chimerism occurred in all 3 dogs within a median of
14 days (range, 9 to 28 days). This is illustrated for dog
G643 in Figure 3. Before DLI, donor 1 (G641) contrib-
uted the least to the 3 hematopoietic systems in recipient
dog G643, but after DLI, both granulocytes and
PBMCs from donor 1 dominated the hematopoietic sys-tem. The shift from trichimerism to all donor 1 chime-
rism was also observed in nucleated cells collected from
marrow and lymph node at necropsy (data not shown).
Peripheral blood cell counts did not change significantly
during the shift in chimerism (data not shown).
GVHD after DLI
All 3 dogs developed liver GVHD, as indicated by
serum levels of alkaline phosphatase (1646, 2004, and
3165 U/L), aspartate aminotransferase (355, 862, and
1201 U/L), alanine aminotransferase (3380, 5440, and
5618 U/L), and bilirubin (5.0, 7.3, and 7.3 mg/dL). Fur-
thermore, skin GVHD, characterized by inflammatory
rashes of the skin of the ears, abdomen, nose, or oral
mucosa, was observed within 30 days after DLI in dog
G362, within 23 days after DLI in dog G513, and
with 32 days after DLI in dog G643. All 3 dogs devel-
oped diarrhea and lost weight. The diagnosis of
GVHD was confirmed by histopathology after the
dogs were euthanized (Figure 4). The skin exhibited
changes ranging from minimal infiltration of PBMCs
to the presence of apoptotic bodies. The liver showed
lymphocytic infiltration in central venous regions and
bile duct lesions, confirming the diagnosis of GVHD.
Atypical cell shapes within bile ducts of G513 indicated
cell regeneration. The jejunum exhibited infiltration of
PBMCs, and the ileum of dog G362 revealed multiple
exploding crypts and crypt abscesses. Thus, all 3 dogs
eventually developed 3-system acute GVHD (aGVHD)
and were euthanized due to their worsening condition.
DISCUSSION
The current study was undertaken with the aim of
targeting the kidney—an organ not among the typical
targets for GVH reactions (i.e., hematopoietic system
Biol Blood Marrow Transplant 14:1201-1208, 2008 1205Immunotherapy Against Kidney Grafts in Hematopoietic TrichimerismFigure 2. Kidney histology of dogs G513, G362, and G643 before sensitized DLI and at necropsy. Biopsies of kidney allografts were done using a per-
cutaneous biopsy needle within 1 week before DLI (left column); sections of both allografted (middle column) and native kidneys (right column) were
collected at necropsy. Tissues were fixed in 10% buffered formalin, fixed, stained with hematoxylin and eosin, and photographed at 100magnification.and epithelial cells from skin, gut, liver, and mucous
membranes)—for allogeneic immune reactions. The
study was prompted by the desire to understand how
graft-versus-tumor effects, typically observed for hema-
tologic malignancies, could be extended to include met-
astatic solid tumor targets. Several clinical studies have
used marrow transplantation to treat various metastatic
solid tumors but with very limited success [3,7]. In these
studies, no tumor- or tissue-associated minor H anti-
gens were used to sensitize donors against the patients’
tumors. Therefore, it would seem reasonable to explore
adoptive immunotherapy with specifically sensitized
lymphocytes to achieve successful treatment of meta-
static solid malignancies. Because no transplantable
tumors exist for random-bred dogs, a functioning kid-
ney allograft with a unique set of minor antigens was
chosen as a surrogate target, because impairment of
kidney function could be easily assessed by serum creat-
inine levels and histopathologic examinations of percu-
taneous kidney biopsies.In an earlier study, we sensitized canine marrow
donors by transplanting kidneys from their respective
mixed hematopoietic chimeric recipients, which they
promptly rejected [8]. Subsequent lymphocyte infu-
sions from marrow donors into chimeras caused con-
version of mixed to all donor chimerism and, in some
cases, GVHD in skin, gut, or liver; however, the
remaining native kidneys did not come under immu-
nologic attack. What explained this lack of graft-ver-
sus-kidney effect, a finding in striking contrast to the
speed with which the marrow donors rejected kidneys
from their chimeric recipients? We hypothesized that
native kidneys lacked the appropriate ‘‘danger signals’’
[13] to attract lymphocytes, and that these signals were
present in the transplanted kidneys. Under this model,
danger signals may be either constitutively expressed
or, in the case of transplantation, induced on stress,
hypoxia, or trauma.
Here we attempted to address the hypothesis in
stable trichimeras that had received marrow grafts
1206 Biol Blood Marrow Transplant 14:1201-1208, 2008S. S. Graves et al.from 2 DLA-identical littermates and a kidney graft
from 1 of the marrow donors. The marrow donor kid-
ney was grafted heterotopically as a putative target for
lymphocytes that had been sensitized to minor H anti-
gens. In all 3 cases, the kidneys were stably engrafted in
the trichimeric recipients due to the induction of toler-
ance established by dual HCT. After immunizing the
first marrow donors against minor H antigens of the
second (marrow and kidney) donors and then infusing
sensitized lymphocytes into the marrow recipients, an
immunologic chain of events occurred that supported
in part our experimental assumption that an organ that
ordinarily is not a target for GVHD reactions might be
targeted under appropriate experimental conditions.
In all 3 cases, the allografted kidneys promptly became
infiltrated with lymphocytes from the sensitized
donors and eventually were rejected.
Consistent with the kidney allograft rejection after
DLI, the previously stable contribution of the marrow/
kidney donor to the trichimeric hematopoiesis disap-
peared. Furthermore, and perhaps expected due to
sharing of minor H antigens among recipients and kid-
ney/marrow donors, host hematopoiesis also disap-
peared along with the appearance of GVHD in
classical target organs, skin, gut, and liver. Somewhat
Granulocytes
0
20
40
60
80
100
1 2 3 4 6 8 11 13 18 20 22 26 34 36 44 45 46 47 48 49
Weeks after HCT
%
 
C
h
i
m
e
r
i
s
m
Recipient
Donor 1
Donor 2
DLI
Mononuclear Cells
0
20
40
60
80
100
1 2 4 6 8 11 13 18 20 22 26 34 35 44 45 46 47 48 49
Weeks after HCT
%
 
C
h
i
m
e
r
i
s
m
Donor 1
Recipient
Donor 2
DLI
B
A
Figure 3. Granulocyte (A) and PBMC (B) chimerism in dog G643 be-
fore and after receipt of sensitized DLI from donor 1. Stable long-term
granulocyte and mononuclear cell trichimerism in the HCT recipient
(A), donor 1 (-) and donor 2 (:) was interrupted after an infusion
of sensitized lymphocytes from donor 1 at week 44. Data points were
obtained by VNTR PCR analysis.in contrast with the widespread immunologic damage
in allografted kidneys; host skin, gut, and liver; and
host and donor 2 hematopoiesis, the hosts’ native kid-
neys showed mild to moderate lymphocytic infiltration
(Figure 2), but renal function was not impaired. These
findings are consistent with the ‘‘danger signal’’
hypothesis [13]. The basis of this model was that
antigen-presenting cells (APC) are activated by signals
from injured cells that had been exposed to toxins,
pathogens, and mechanical damage [23]. Also falling
into this category were transplanted organs in which
surgical and or ischemic damage occurred, resulting
in activation of antigen-presenting cells. Thomas
et al. [24] reported that long-term renal allografts
were established in histocompatibility complex–mis-
matched macaques treated with deoxyspergualin with
or without immunotoxin (anti–CD3-CRM9, a mutant
diphtheria toxin). The proposed mechanism of action
of deoxyspergualin was the prevention of APC matura-
tion, suppressed expression of costimulatory mole-
cules, and establishment of a state of tolerance.
Although in our trichimeric model the transplanted
kidneys demonstrated stable engraftment, undetected
molecular events may have been involved in the
graft-versus-host reaction after DLI. In the transcrip-
tional profiles of histologically normal living donor
kidney allografts, Park et al. [25] found ongoing injury
response and inflammation at 1-year posttransplanta-
tion, with up-regulated genes associated with inflam-
mation, immunity, or response to injury.
Despite this evidence of susceptibility to rejection
in the transplanted kidneys, we nonetheless found
only limited infiltration of lymphocytes within the na-
tive kidneys. Perhaps more time was needed for renal
function impairment to occur; however, the observa-
tion time was cut short by the development of life-
threatening severe GVHD in the skin, gut, and liver.
Nevertheless, it is clear that we successfully induced
an immune response against a kidney tissue not nor-
mally targeted in GVHD. Further experiments with
this model may shed light on immunologic mecha-
nisms to avert GVHD in many normal tissues and
may ultimately lead to methods for specifically target-
ing these responses against solid tumors. Next-gener-
ation sequencing studies are currently underway to
identify coding of nonsynonymous single-nucleotide
polymorphisms in breeders and their offspring that
are unique to HCT recipients and expressed in tissues.
Some of these polymorphisms may display ubiquitous
tissue expression, whereas others may be restricted to
hematopoietic cells or individual organs, such as kid-
neys, and thus define sets of H antigens that could be
used to sensitize the marrow donor against a candidate
target organ. Accordingly, subsequent DLI would
result in immune reactions restricted to the desired
target organ (e.g., marrow or kidney) without the de-
velopment of GVHD.
Biol Blood Marrow Transplant 14:1201-1208, 2008 1207Immunotherapy Against Kidney Grafts in Hematopoietic TrichimerismFigure 4. Histology of skin, liver and gut of dogs G513, G362, and G643 at necropsy. Tissues were fixed in 10% buffered formalin, sectioned, stained
with hematoxylin and eosin, and photographed at 250 magnification. Mononuclear cell infiltrates (/) and apoptotic epithelial cells or damaged oblit-
erated duct structures (B) are indicated.ACKNOWLEDGMENTS
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